Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan

Introduction: The preferred first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive (EGFRm) advanced/metastatic non-small lung cancer (NSCLC) are EGFR-tyrosine kinase inhibitors (TKIs). However, most patients treated with 1L first- or second-generation (1G/2G) EGFR-TK...

Descripció completa

Dades bibliogràfiques
Autors principals: Jae Cheol Lee, Jen-Yu Hung, Young-Chul Kim, Gee-Chen Chang, Seung Soo Yoo, Sheng-Hsiung Yang, Keith L Davis, Saurabh P Nagar, Aliki Taylor, Sung Yong Lee, Jin-Yuan Shih
Format: Article
Idioma:English
Publicat: West Asia Organization for Cancer Prevention 2021-05-01
Col·lecció:Asian Pacific Journal of Cancer Biology
Matèries:
egfr mutation
egfr-tki
nsclc
osimertinib
t790m
Accés en línia:http://www.waocp.com/journal/index.php/apjcb/article/view/663

Internet

http://www.waocp.com/journal/index.php/apjcb/article/view/663

Ítems similars